June 3, 2021 05:26 PM EDT

#ASCO21: Nanobiotix says early data show 'very strong' signal that its nanoparticles can dial up antitumor response

Nicole DeFeudis

Editor

While cancer immunotherapies have shown promise, Nanobiotix thinks it can use nanoparticles to dial up the tumor killing effect of radiation and checkpoint inhibitors. And …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO21: Nanobiotix says early data show 'very strong' signal that its nanoparticles can dial up antitumor response

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

#AS­CO21: Nanobi­otix says ear­ly da­ta show 'very strong' sig­nal that its nanopar­ti­cles can di­al up an­ti­tu­mor re­sponse

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

#ASCO21: Nanobiotix says early data show 'very strong' signal that its nanoparticles can dial up antitumor response